abscopal effect, A5A26 09.03P08.02

Acute myeloid leukemia, A31 P09.01

Adoptive Cell Therapy, A25A38 P08.01P09.13

adoptive cellular therapy, A40 P09.17

Adoptive T cell therapy, A3A9A32 09.01P01.03P09.02

AML, A24A25A36 P07.01P07.02P09.10

AML chemotherapy, A27 P08.05

anaplastic thyroid carcinoma, A22 P06.01

anti-PD1, A5 09.03

antibodies, A19 P03.05

antibody therapy, A1 03.06

APEX proximity labeling, A9 P01.04

B cell, A13 P02.03

barcoded-multimer, A3 08.03

Bifunctional antibodies, A7 12.05

Bispecific monoclonal antibody, A8 P01.01

Bispecific antibody, A4 09.02

bladder cancer, A2A27 06.04P08.04

brain tumors, A18A38 P03.04P09.13

Breast cancer, A29 P08.08

bystander killing, A8 P01.01

CAF09b, A16 P03.01

cancer immunotherapies, A21 P04.03

cancer immunotherapy target, A19 P03.07

Cancer nanomedicine, A43 P09.22

Cancer Testis Antigen, A29 P08.08

Cancer Vaccine, A17A18 P03.03P03.04

Cancer-Immunotherapy, A1 03.05

cancer_vaccine, A19 P03.05

CAR T cells, A3A22A23A32A35A36A7 09.01P06.01P06.02P09.02P09.06P09.0912.04

carcinoma, A33 P09.03

CD155, A33 P09.03

CD20, A1 03.06

CD38, A6 12.03

CD40-activated B cells (CD40Bs),A24  P06.04

CD47, A6 12.03

CD8 T cell Cooperation, A35 P09.07

CD8+ T cells, A42 P09.20

Cell therapy, A4 09.02

Chemokine-receptor interaction, A9 P01.04

Chimeric antigen receptor (CAR) T cells, A31 P09.01

chromatin, A16 P02.09

colorectal cancer, A14A29 P02.06P08.07

Combination immunotherapy, A2 06.03

combinatorial therapy, A28 P08.06

companion diagnostics, A21 P04.03

complement activation, A1 03.06

CRC, A42 P09.19

CRISPR screen, A30 P08.09

ctDNA, A21 P04.02

CTLA-4, A36 P09.10

cystatin F, A33 P09.04

cysteine cathepsins, A33 P09.04

cytarabine resistance, A27 P08.05

Cytokine-Induced Killer cells, A25 P08.01

cytotoxicity, A8 P01.02

Dendritic Cells, A25 P07.02

dexamethasone, A37 P09.11

electrochemotherapy, A26 P08.03

Endogenous retrovirus, A17A40 P03.03P09.16

Entropy, A15 P02.07

EVs, A24 P07.01

fully automated platform, A12 P02.02

Galectin-9, A11 P01.07

gastric adenocarcinoma, A37 P09.11

gene regulation, A16 P02.09

gene therapy, A26 P08.03

Glioblastoma, A15A39 P02.08P09.14

granule-dependent cytotoxicity, A33 P09.04

gut microbial metabolites, A37 P09.11

Head and neck squamous cell carcinomas, A36 P09.08

Hepatocellular carcinoma, A15 P02.07

HERV-K, A19 P03.05

high throughput screening, A28 P08.06

HLA system, A38 P09.12

HLA-G, A10 P01.06

HNSCC, A39 P09.15

HVEM, A12 P02.01

IL-2, A5 09.03

IL-22, A33 P09.03

ILC2, A14 P02.06

Immune cell infiltration, A43 P09.23

immune cell killing, A28 P08.06

immune cell landcape evolution, A15 P02.08

Immune checkpoint blockade, A18 P03.04

immune checkpoint inhibitor, A14A2A27 P02.0506.04P08.04

immune checkpoint targeting, A10 P01.06

Immune escape, A38 P09.12

Immune evasion, A11 P01.07

immune monitoring, A20 P04.01

Immune Profiling, A13 P02.04

Immunology, A42 P09.20

Immunomodulation, A25A36 P07.02P09.10

Immunosuppression, A23 P06.03

immunotherapy, A14A20A22A24A30A32A35A35 P02.06P03.08P05.01P06.04P08.09P09.02P09.06P09.07

Indoleamine-2,3-dioxygenase, A39 P09.14

Influenza, A41 P09.18

Innate Cell Engagers, A6 12.03

Innate immune checkpoint blockade, A7 12.05

interleukin-12, A26 P08.03

Jurkat cells, A8 P01.02

Killer Ig-Like Receptors, A42 P09.20

LDHC, A29 P08.08

lectins, A8 P01.02

leukaemia, A3 08.03

leukemia derived DC, A20 P04.01

Liquid Biopsy, A21 P04.02

liver hepatocellular carcinoma, A12 P02.01

Lymphoma, A34 P09.05

Lysosome, A34 P09.05

Macrophages, A35 P09.07

Malignant Pleural Effusions, A30 P08.10

medicines authorisation, A21 P04.03

Melanoma, A4 09.02

MelARV, A40 P09.16

Microbiome, A14 P02.05

miRNA, A24 P07.01

Molecular mimicry, A19 P03.06

MRD, A21 P04.02

Multiplex immunofluorescence, A12 P02.02

Myeloid, A15 P02.07

Neoantigen, A38 P09.12

neoantigen-specific TCR, A40 P09.17

neoepitope, A3 08.03

nephroblastoma, A43 P09.23

Neuroblastoma, A2A7A23A30 06.0312.05P06.03P08.09

NSCLC, A22 P05.01

Nucleolin, A23 P06.02

oncolytic virotherapy, A43 P09.21

oncolytic virus, A7A39A41 12.04P09.15P09.18

Organ-on-a-chip, A10 P01.05

organoids, A42 P09.19

Pancreatic Adenocarcinoma, A13 P02.03

Pathogen antigens, A19 P03.06

PD-1 gene silencing, A9 P01.03

Peptide vaccine, A16A17 P03.01P03.02

Personalised immunotherapy, A11 P01.07

Personalized tumor vaccine, A20 P03.08

photodynamic therapy, A27 P08.04

PLAP (placental alkaline phosphatase),A8  P01.01

Platelets, A22 P05.01

Programmed Death-1 inhibitors, A39 P09.14

prostate cancer, A17 P03.02

prostatic acid phosphatase, A17 P03.02

Protom pump inhibitors, A14 P02.05

Radiochemoimmunotherapy, A26 P08.02

Radiotherapy, A30 P08.10

rational design, A43 P09.22

resistance, A5 09.04

Robo4, A1 03.05

ROR1 receptor, A22 P06.01

screening of therapeutic inhibitors, A9 P01.04

ScRNA sequencing, A15 P02.08

Self-Antigen, A1 03.05

Single-cell RNA sequencing, A31 P09.01

slice cultures, A39 P09.15

Solid tumor, A25 P08.01

Spatial Biology, A13 P02.04

spatial model, A43 P09.21

STING, A30 P08.10

Stress Granules, A29 P08.07

T cell death, A5 09.04

T cell engineering, A40 P09.17

t cell exhaustion, A16 P02.09

T cell factor 1 (TCF-1),A9  P01.03

T cell lymphoma, A36 P09.09

T cell response, A20 P03.08

T cells, A10A23 P01.05P06.03

Targeted therapy, A2 06.04

Tertiary Lymphoid Structures, A13 P02.03

Therapeutic concepts, A34 P09.05

therapeutic resistance, A43 P09.21

TIGIT, A2 06.03

TNF, A41 P09.18

Transmigration, A10 P01.05

Treg depletion, A5 09.04

Triple negative breast cancer, A23 P06.02

tumor associated macrophages, A42 P09.19

tumor immunotherapy, A12 P02.01

Tumor microenvironment, A3A10A12A35A36A38 09.01P01.06P02.02P09.06P09.08P09.13

Tumor-associated antigens, A16A19A24A7 P03.01P03.06P06.0412.04

Virus-Encoded Virus-Like-Particles, A17 P03.03

Virus-like vaccine, A40 P09.16

VOCs above serum and cell culture supernatants, A20 P04.01

Vpx protein, A27 P08.05